Navigation Links
A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer

A recent study has shown that a chemotherapy regimen combining vinorelbine (Navelbine) and mitoxantrone (Novantrone)// with the corticosteroid prednisone is effective in the treatment of hormone-refractory prostate cancer . Specialists say this treatment should be offered to symptomatic patients earlier in their disease.

However researchers added that a larger phase 2 study of this treatment regimen is planned. From a group of 66 patients who had advanced prostate cancer, the investigators recruited 12 for whom previous hormone therapy had failed in at least 3 lines of treatment.

The investigators included patients who had undergone palliative radiotherapy at any point during their disease. The patient’s median age was 67 years, with a range of 60 to 81 years. The patient’s median Eastern Cooperative Oncology Group performance status was 1, with a range of 0 to 2. All the patients had bone metastases, some with multiple sites. One patient had lymph node metastasis, and 1 had visceral disease. Three patients had significant ischaemic heart disease.

Each treatment cycle consisted of 10 to 12 mg/m2 of mitoxantrone on day 1, followed by 20 mg/m2 of vinorelbine on days 1 through 8. This cycle was repeated every 3 weeks. The patients also received 12.5 mg daily of prednisone. A total of 95 cycles were given, with a median of 7 cycles per patient and a range of 5 to 9 cycles per patient. Two patients repeated the treatment at 6 months and 12 months after the initial treatment. Among these patients, 50% had a marked decrease in pain and improvement in ECOG performance status, according to specialists. In 8 cycles, due to the response to treatment, the dose of vinorelbine was reduced 50% and in 4 cycles it was reduced 75%. The mitoxantrone dose was reduced 50% in 5 cycles. Although 1 patient had a drop in prostate specific antigen (PSA) of more than 50%, the computed tomography findings did not show an equivalent response.

The patients' median time to progression was 10 months, with a range of 6 months to over 20 months. Two patients are living; 8 died due to disease progression; and 2 died of other causes. The toxicity episodes consisted of 6 neutropaenic events, all afebrile. Otherwise, the investigators documented no Grade 4 haematological toxicity and no non-haematological toxicity.
'"/>




Related medicine news :

1. Consensus on "Combination Therapy" for Breast Cancer
2. Drug Combinations May Boost Stroke Risk
3. Combination therapy to treat breast cancer
4. Combination regime may work against prostate cancer
5. Smoking and Breast Cancer - A Deadly Combination
6. New Drug Combination Found To Improve Memory in Alzheimer’s Patient
7. Combination Therapy Effective In Improving Lung Cancer Survival
8. Combination Therapy Found To Improves Stroke Recovery
9. Combination Therapy Found To Be More Effective In Treating Brain Cancer
10. Combination of Clopidogrel-aspirin is better for preventing stroke than only aspirin
11. New Combination Therapy Option for HIV Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa ... contributed a medical article to the newly revamped Cosmetic Town journal ... the hair transplant procedure known as Follicular Unit Extraction (FUE). , ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
(Date:10/2/2017)... 2017 Halo Labs announces the European launch of their ... HORIZON at MIBio 2017 in Cambridge, U.K ... matter in biopharmaceutical samples with unprecedented speed and sensitivity while using ... Backgrounded Membrane Imaging. ... subvisible particle analysis system ...
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
Breaking Medicine Technology: